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Background: Tumour necrosis factor (TNF) blocking agents decrease C reactive protein (CRP) levels in
rheumatoid arthritis (RA). It has been shown that CRP may contribute to complement activation in RA.
Objective: To assess the effect of intravenous infliximab treatment on complement activation, especially
that mediated by CRP, in RA.
Methods: 35 patients with active RA (28 joint count Disease Activity Score (DAS28) .4.4) were treated
with intravenous injections of infliximab (3 mg/kg, at weeks 0, 2, 6, 14, and 22). Clinical response and
plasma levels of complement activation products, of CRP and of CRP-complement complexes, which are
specific markers for CRP mediated complement activation, were assessed at the indicated time points up to
22 weeks. The relationship between CRP and CRP-complement complexes was analysed by paired t test
between two time points and by generalised estimated equation, to test differences of variables over time.
Results: At 2 weeks after the first dose, infliximab significantly reduced overall C3 and C4 activation and
plasma levels of CRP and CRP-complement complexes were also significantly reduced at this time point.
The effects of infliximab on CRP and complement continued throughout the observation period and were
more pronounced in patients with a good response to infliximab treatment.
Conclusion: Treatment with infliximab decreases plasma levels of CRP and CRP dependent complement
activation products and concomitantly may reduce complement activation in RA. Complement activation
may be among the effector mechanisms of TNF in RA.
D
uring the past decade, it has become clear that
cytokines have a key role in the pathogenesis of
rheumatoid arthritis (RA). In particular the cytokine
tumour necrosis factor a (TNFa) is a major player in the
inflammatory cascade. Expression of TNFa and its receptors
has been demonstrated in RA synovial tissue.1 Furthermore,
in vitro experiments with synovial cells2 and animal studies3
showed reduction of other inflammatory cytokines upon
blockade of TNFa activity. This has led to the concept that
TNFa is an essential mediator in inflammation in the
rheumatoid joints, and has stimulated the development of
drugs that block TNFa as a treatment of RA. Indeed there is
now ample evidence that anti-TNF agents improve the
clinical course of RA.4–7
In addition to the action of cytokines, activation of
complement seems to be another important contributor to
inflammation in RA. For example, high levels of complement
activation products have been demonstrated in the joints and
to a lesser extent in the circulation of patients with RA.8 9
Moreover, intervention studies with complement inhibitors
in animal models of arthritis have confirmed that comple-
ment has an important role in the pathogenesis of
inflammation in the joints.10 11 Activation of complement
induces inflammation by generating several peptides and
protein complexes, such as C5a and C5b–C9 complexes,
which activate and stimulate endothelial and inflammatory
cells.12–14 Immune complexes are considered to be the main
inducers of complement activation in RA.15 16 However, other
compounds can activate complement as well. For example,
the acute phase protein, C reactive protein (CRP), a member
of the pentraxin family,17 bound to a ligand can activate the
complement system via a classical pathway.18 19 Recently, we
reported increased levels of complexes between the acute
phase protein CRP and activated C3 or C4 in the plasma of
patients with RA,20 suggesting that CRP contributes to
complement activation in RA.21 Neutralisation of TNFa
decreases plasma levels of CRP in patients with RA.17
Hence, one may postulate that CRP mediated complement
activation may amplify the inflammatory effects of TNFa.
However, to our knowledge little, if anything, is known about
the effect of anti-TNF drugs on complement activation in
patients with RA.
In this study we investigated the effect of treatment with
the anti-TNF monoclonal antibody (mAb), infliximab, on
overall complement activation, as well as on CRP levels and
CRP mediated complement activation in patients with RA.
PATIENTS AND METHODS
Study protocol
Thirty five patients with active RA, for whom treatment with
standard disease modifying antirheumatic drugs had failed,
were selected to enter our study. Each patient fulfilled the
American College of Rheumatology criteria for diagnosis of
RA and had a 28 joint count Disease Activity Score (DAS28)22
.4.4, indicating that they had active disease. The study group
comprised 29 women and six men with a mean (SD) age of
52 (1) years (range 25–73), and a mean (SD) disease
duration of 10 (7) years (range 1–24).
All patients received 3 mg/kg of infliximab (Centocor,
Malvern, Pa) at weeks 0, 2, 6, 14, and 22. Each patient was
clinically examined for assessment of response to treatment
before each anti-TNF injection. Clinical response was defined
as improvement of the DAS28 score according to criteria
established by the EULAR.23 Briefly, a good responder was
defined as a patient in whom the DAS28 had improved by
.1.2 and who had a DAS28 ,3.2 at the time of evaluation. A
Abbreviations: CRP, C reactive protein; DAS28, 28 joint count Disease
Activity Score; ELISA, enzyme linked immunosorbent assay; GEE,
generalised estimating equation; IL, interleukin; mAb, monoclonal
antibody; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFa, tumour
necrosis factor a
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moderate responder was defined as a patient who had either
an improvement of DAS28 of 0.6–1.2 and who had a DAS28
,3.2, or an improvement of DAS28 .0.6 and a current DAS
of 3.2–5.1, or who had an improvement of DAS28 .1.2 and a
current DAS28 .5.1. Patients who did not fulfil these criteria
were considered to be non-responders.
The study protocol was approved by the medical ethical
committee of the VU University Medical Centre. Each patient
had given informed consent to participate in the study.
Blood samples collection
Before every infliximab infusion, blood was collected from
each patient in citrate or EDTA containing tubes . Plasma was
obtained by centrifugation at 1300 g for 10 minutes at 4 C˚.
EDTA or citrate plasma was immediately frozen and kept at
270 C˚ until tests were performed.
To establish normal values for complement, plasma
samples were also obtained from 33 healthy people, and
processed in a similar way to the samples from the patients.
Laboratory measurements
Activation of complement
Activation of complement system was assessed by specific
enzyme linked immunosorbent assays (ELISAs) for measure-
ment of plasma levels of activated C4 and C3.19 We used
specific mAbs against neo-epitopes exposed on activated
fragments as capture antibodies, and biotinylated polyclonal
sheep antibodies against C4 and C3, respectively, to detect
bound complement fragments. As these assays do not
discriminate between C4b, C4bi, or C4c, or between C3b,
C3bi, or C3c, the activation products detected in the assays
are further referred to as C4b/c and C3b/c, respectively.
Results were expressed as nmol/l C4b/c or C3b/c, referring to
an in house standard with known levels of activation
products.
CRP and CRP mediated complement activation
CRP was measured with a specific ELISA as described
previously.24 CRP mediated complement activation was
evaluated using specific ELISAs for covalently bound com-
plexes between CRP and activated C4 or C3.19 Briefly, CRP
and CRP complexes were isolated from plasma through
calcium dependent affinity for phosphorylcholine coupled to
Sepharose beads. After extensive washing of the beads, CRP
and complexes were eluted with EDTA containing buffer, and
applied to ELISA plates coated with appropriate anticomple-
ment component mAbs as catching antibodies. Bound CRP-
C4d and CRP-C3d complexes were detected with biotin
conjugated mAb against CRP. The affinity based separation of
CRP and CRP complexes was necessary to reduce interference
in the ELISA by the excess of complement components
present in the sample to be tested, and was performed in the
presence of 0.5 M NaCl to prevent in vitro complement
activation. Levels of CRP complexes in samples were
expressed as mU/ml.
Rheumatoid factor (RF) levels were assessed with an
ELISA, in which human IgG was used as coating and
peroxidase conjugated mouse antihuman IgM as detecting
antibody. Circulating immune complexes were measured
with the 125I-C1q binding test.25
Analysis of data
The GraphPad InStat program, version 3.0 (GraphPad
Software, San Diego, CA), was used to analyse the data.
Data are given as mean and standard deviation in cases of
normal distribution, and median and range in cases of non-
normal distribution. The difference between variables in
patients and those in healthy people was analysed with
Mann-Whitney tests. The effect of anti-TNF on levels of a
given variable was evaluated by analysing levels before and at
2 weeks after the first dose of anti-TNF using Wilcoxon
matched pairs signed ranks tests. Measures at various time
points after treatment were compared with baseline using
analysis of variance for repeated measurements. The relation
of complement parameters to clinical response was analysed
by generalised estimating equations (GEEs). A GEE is a
regression technique for studying intervariable relationships
in longitudinal studies. This technique corrects for the
dependency of observations within the patients.26 When this
technique is used, time as well as time independent and time
dependent covariates are taken into account. In this set of
data we analysed the relation between CRP, CRP complexes,
and complement with the DAS28 response from 2, 6, 14 and
22 weeks (outcome variable). In all GEE analyses a correc-
tion for the baseline DAS28 score was performed and GEE
analyses were performed with STATA (version 7).
A two sided value of p,0.05 was considered to reflect a
significant difference.
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Figure 1 Effect of infliximab (anti-TNF) treatment on Disease Activity
Score 28 (DAS28): DAS28 was assessed in each patient before each
injection of infliximab. Note that at 2 weeks, in all patients DAS28 had
decreased, but that in time in some patients this decrease became less or
even reversed (p value for repeated measurement of analysis of variance
,0.0001).
Table 1 Plasma levels of the complement activation products C3b/c and C4b/c in the
patients with RA before the start of infliximab treatment in comparison with those in
healthy volunteers
Healthy volunteers (n = 33) Baseline values in patients with RA (n = 35)
Maximum Minimum Mean (SD) Maximum Minimum Mean (SD)
C3b/c 28 8.3 15 (4.7)* 53 5 27.3 (10.8)*
C4b/c 20 1.7 6.9 (4.7)* 152 5 42.6 (34.9)*
*p,0.0001 for the difference between healthy controls and patients (Mann-Whitney test).
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RESULTS
Clinical course of the patients upon infliximab
treatment
Thirty five patients were included in the study. The DAS28
was assessed in every patient before the start of infliximab
treatment and before each subsequent injection to establish
clinical responses to treatment. Figure 1 shows the DAS28 of
the whole group at different time points. At the first
evaluation point—that is, at 2 weeks after the first injection,
all the patients showed clinical improvement, as reflected by
a decreased DAS28 compared with the score at baseline. At
the later time points, some patients no longer responded to
infliximab according to the criteria described in ‘‘Patients and
methods’’. For example, at the end of the observation
period—that is, at 22 weeks after the first injection, 10
showed a good response, 20 had a moderate response, and 5
had no response to the treatment, according to the criteria
described in ‘‘Patients and methods’’.
Effect of infliximab on complement activation
Plasma levels of C3b/c and C4b/c, reflecting activation of C3
and C4, respectively, in the patients before the start of
infliximab treatment were indeed significantly higher than
levels in healthy volunteers (table 1), 85 and 88% of the
patients with RA having raised C3b/c and C4b/c, respectively,
as compared with normal values (p,0.0001 in both cases for
the difference between patients and healthy controls, Mann-
Whitney test).
At 2 weeks after the start of infliximab treatment all
patients were responders according to change of the DAS28.
p < 0.0001
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Figure 2 Activation of complement before treatment and at 2 weeks
after the first injection of infliximab. Data represent plasma levels of
C3b/c (A) and C4b/c (B). Note that both measures had significantly
decreased after treatment with infliximab.
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Figure 3 Effect of infliximab treatment on plasma levels of (A) CRP and
(B, C) CRP-complement complexes: (B) CRP-C3d; (C) CRP-C4d, which
reflects CRP mediated complement activation. Note that both CRP and
CRP-complement complexes significantly decreased upon treatment (p
values for all panels are ,0.001).
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Hence, we evaluated the effect of infliximab on complement
activation by comparing levels of C3b/c and C4b/c at 2 weeks
after treatment with those at baseline, because at that time
all patients had responded to the treatment and levels of
complement activation parameters, C3b/c and C4b/c, were
both significantly lower than levels before treatment (fig 2).
RF can form immune complexes with autologous IgG and
hence may be involved in complement activation in RA. To
analyse the effect of infliximab on circulating levels of RF, we
measured the plasma levels of IgM RF before and after the
first injection—that is, at 2 weeks. Levels at 2 weeks were
comparable with baseline levels (data not shown). Also,
levels of circulating immune complexes, as assessed with the
125I-C1q binding assay, had not changed at 2 weeks after the
start of treatment as compared with baseline levels (data not
shown).
Plasma levels of CRP and CRP mediated complement
activation
Using specific ELISAs, we measured plasma levels of CRP and
of CRP-C3d and CRP-C4d complexes in the patients before
and after start of the infliximab treatment—that is, at 2, 6,
14, and 22 weeks. Before treatment 29/35 (83%) patients had
raised CRP, and 24 (69%) and 31 (89%) had increased levels
of CRP-C3d and CRP-C4d complexes, respectively, as
compared with normal levels. Plasma levels of CRP sig-
nificantly decreased in the patients during treatment (fig 3A),
as did those of both CRP-complement complexes (figs 3B and
C).
CRP and complement in relation to clinical response
The relationship between variations in complement or CRP
parameters and clinical response to infliximab was assessed
before and after 14 weeks of treatment. Based on the clinical
response to treatment at this time point, patients were
divided into three different subgroups—that is, patients with
a good, moderate, or no response, as defined in ‘‘Patients and
methods’’. The decrease of CRP and C3b/c levels was more
pronounced in the patients with a good response. C4b/c
levels, however, did not show this relationship (table 2).
Plasma levels of CRP-complement complexes decreased six-
to sevenfold in the group of responders, which was
significant, whereas they dropped non-significantly about
twofold in the group of non-responders. Analysis of the data
at other time points also pointed to more pronounced
decreases of these variables in patients who showed a good
response to infliximab, in comparison with those who did not
respond.
The relationship between complement or CRP parameters
and clinical responses upon treatment with infliximab were
analysed with GEEs. These analyses showed a significant
association between a decrease of CRP and a good response
(p,0.01). Significant associations of CRP-C3d and CRP-C4d
with a good response were also seen (p,0.01). However,
these relationships were less strong when a correction was
made for CRP (the corresponding p values for CRP-C3d and
CRP-C4d were 0.34 and 0.06, respectively). No significant
associations between C3b/c and C4b/c and clinical response
were found (p=0.56 and p=0.84. respectively).
DISCUSSION
It has been suggested that TNFa blockade exerts its anti-
inflammatory effects by interfering with the recruitment of
leucocytes into the joints, and by attenuating the synthesis of
several cytokines such as interleukin (IL) 1 and IL6, and
other mediators such as matrix metalloproteinases-1 and -3,
and vascular endothelial growth factor. Here we show that
infliximab treatment reduces plasma levels of activated C4
and C3 of the complement system, and of CRP-complement
complexes in patients with RA.
Various studies point to activation of the complement
system as a crucial event in the inflammatory cascade in
rheumatoid joints RA.27 28 Raised levels of C3a and C5a
indeed have been noted in the synovial fluid and plasma of
patients with RA,29231 and these potent inflammatory
peptides may play a part in inflammatory cell recruitment
to the synovial fluid and tissue. Also, in this study we found
increased plasma levels of C3b/c and C4b/c in the majority of
patients with RA before the start of infliximab treatment. We
did not investigate the origin of these activation products of
the complement system. Considering that several studies
have shown increased levels of complement activation
products in the joints, in particular, we assume that the
increased plasma levels were due to spill over from the joints,
although extra-articular activation—for example in patients
with subclinical vasculitis,9 might also have contributed to
the activation.
As all patients showed clinical responses upon adminis-
tration of infliximab at 2 weeks after the start of the
treatment, we decided to analyse the effect of anti-TNF on
complement activation itself by comparing levels at 2 weeks
with those at baseline. In this way, the results were not
blurred by analysing non-responding patients as well. A
significant decrease of complement activation at 2 weeks was
seen. Immune complexes involving RFs are frequently
considered as a major cause of complement activation in
RA.15 16 Hence, an obvious explanation for the effect of
infliximab on complement activation would be that this
treatment affected levels of RFs or immune complexes.
However, we found no clear differences in these measures at
2 weeks as compared with levels at baseline. These findings
argue against an effect of infliximab on immune complexes
or RFs as an explanation for the observed effects of anti-TNF
on complement.
A decrease in plasma levels of CRP, a member of the
pentraxin family, which acts as an acute phase protein in
Table 2 Plasma levels of CRP, CRP-complement complexes, and complement activation products in patients with RA treated
with infliximab, classified according to their clinical response (good, moderate, or no response) at 14 weeks after the start of
treatment
Good (n = 9) Moderate (n = 17) No response (n = 9)
Plasma
levels
Before
treatment
After
treatment p Value
Before
treatment
After
?treatment p Value
Before
treatment
After
treatment p Value
CRP 33 (24.8) 2.2 (1.8) ,0.01 31.6 (25.7) 15.2 (26.2) ,0.001 57.2 (48.6) 45.6 (44.4) 0.160
C3b/c 33.3 (11.8) 22.8 (6.9) 0.054 24.6 (10.9) 17.5 (6.4) ,0.01 27.4 (9.1) 34.1 (25.2) 0.547
C4b/c 60.1 (49.8) 58 (45.6) 0.91 37.4 (31.8) 22.9 (13.4) 0.120 39 (25.5) 23.4 (6.6) 0.431
CRP-C3d 406 (417.5) 62 (65.2) ,0.05 434 (502.4) 145 (276.6) ,0.001 1043 (1249) 535 (507) 0.250
CRP-C4d 632 (686.6) 83 (142.6) ,0.05 370 (379.7) 148 (334) ,0.01 1071 (1403) 598 (806) 0.312
Data are shown as mean (SD) before and after 14 weeks after treatment. p Values show the differences between baseline and the follow up in every group
(Wilcoxon matched pairs test).
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humans, as a consequence of TNF blockade has been
reported before by Elliott et al.32 Human CRP can activate
the complement system via a classical pathway and we have
shown previously that activation of the complement system
in RA is partly mediated through this pentraxin.20 Hence, the
effect of infliximab on complement may well be related to the
effect of the antibody on CRP levels. Indeed we observed a
significant decrease of CRP-complement complexes, which
specifically reflect complement activation through CRP,19
upon infliximab treatment. However, a significant number
of patients still had increased levels of complement activation
products despite effective anti-TNF treatment and lower CRP
levels, which suggests that part of the complement activation
in RA is independent of CRP, and results, for example, from
interaction of complement with immune complexes.
Intervention studies in animal models for arthritis indicate
a pivotal role for complement activation in the pathogenesis
of arthritis.10 33 34 Considering the observed effects of inflix-
imab, one may postulate that the clinical responses to
infliximab in RA are in part due to its effects on complement.
To substantiate this further we analysed the effect of
infliximab on complement in patients who responded well
to the treatment in comparison with patients who did less
well. When analysing the relationship between clinical
responses and complement at one time point, we observed
a somewhat more pronounced effect of infliximab on
complement in patients who responded well. However, the
differences were not marked. One might argue that these
effects of infliximab on complement and on the clinical
course may not occur at the same time. Hence, we also
analysed by GEE the effect of infliximab on complement and
clinical response by considering the changes at all time points
after the start of the treatment. In this way a somewhat more
pronounced effect of infliximab was seen in patients with a
good response, but again the differences between poor and
good responders were not very strong. Among the explana-
tions for this moderate difference between good and poor
responders are the somewhat small numbers of patients
analysed, as well as the variability of responses in time in
individual patients.
Several studies have shown that recombinant cytokines
such as IL2 and TNF may induce complement activation
when given at high doses to patients.35 36 In this study we
show that blockade of an endogenous cytokine such as TNF
in RA attenuates complement activation in vivo. Blockade of
the activity of another proinflammatory cytokine, IL1, with
IL1 receptor antagonist, significantly improves RA.37 Data on
the effect of a IL1 receptor antagonist on complement
activation in RA are not yet available. However, we have
shown that the effect of IL1 receptor antagonist treatment on
C3a levels is significant in septic patients.38 Taking these data
together, one may postulate that cytokines released during
inflammation trigger complement activation, presumably
through mechanisms involving CRP. We suggest that
reduction of this activation contributes to the anti-inflam-
matory effects of anti-cytokine reagents in humans.
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